Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• At least 50 years of age and diagnosed with mild to moderate Alzheimer's disease or healthy volunteers

• fluent in reading and speaking English

• AD patients must have a reliable study partner who will be in frequent contact with the patient and comply with protocol requirements

• AD patients who have received AChEIs or memantine for at least 4 months and on stable therapy for at least 2 months prior to starting study drug

Exclusion Criteria:

• Have a history of serious infectious disease affecting the brain, head trauma, cancer, drug or alcohol abuse in the past 5 years

• Have serious or uncontrolled health problems or laboratory tests

• Multiple or severe drug allergies

• Prior participation in an active immunization study